PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Endocyte and ITM Announce Supply Agreement for No-Carrier-Added Lutetium for the Phase 3 VISION Trial
WEST LAFAYETTE, Ind. and MUNICH, Germany, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), and ITM Isotopen Technologien München AG (ITM), a specialized radiopharmaceutical company, today announced a supply agreement under which ITM will supply to Endocyte the medical radioisotope
View HTML
Toggle Summary Endocyte Announces Fourth Quarter and Full Year 2017 Earnings Conference Call
West Lafayette, Ind. , Feb. 22, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. , (NASDAQ:ECYT) announced today that the company will host a conference call on Monday, Feb. 26th , at 8:30 a.m. EST to discuss its fourth quarter and full year financial results and provide an operational update.
View HTML
Toggle Summary Endocyte Added to NASDAQ Biotechnology Index  
WEST LAFAYETTE, Ind. , Dec. 15, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment,  today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ:NBI).
View HTML
Toggle Summary Endocyte to Present at the Jefferies 2017 London Healthcare Conference
WEST LAFAYETTE, Ind. , Nov. 09, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company's management team will present at the Jefferies 2017 London Healthcare Conference
View HTML
Toggle Summary Endocyte Reports Third Quarter Financial Results
        - Plans to Initiate Phase 3 Registration for 177 Lu-PSMA-617 Accelerated by Radiomedix Agreement to Transfer Active U.S. Investigational New Drug Application (IND) to Endocyte -       - The University of Sydney and ANZUP Cancer Trial Group Set to Initiate Trial of 177 Lu-PSMA-617 versus
View HTML
Toggle Summary Endocyte Announces Third Quarter 2017 Earnings Conference Call
WEST LAFAYETTE, Ind. , Oct. 30, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. , (NASDAQ:ECYT) announced today that the company will host a conference call on Monday, Nov. 6th , at 4:30 p.m. EST to discuss its third quarter financial results and provide an operational update.
View HTML
Toggle Summary Endocyte Announces Exclusive Worldwide License of Phase 3 Ready PSMA-Targeted Radioligand Therapy for Development in Prostate Cancer
- Transformational Transaction Provides Endocyte with the Most Advanced Targeted Radioligand Therapy in Development for Prostate Cancer, Addressing a Greater than $1 Billion Market Opportunity - -  High Response Rates Demonstrated in Late Stage Prostate Cancer Patients in Clinical Data Presented at
View HTML
Toggle Summary Endocyte to Present at the 2017 Cantor Global Healthcare Conference
WEST LAFAYETTE, Ind. , Sept. 19, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that the company's management team will present at the 2017 Cantor
View HTML
Toggle Summary Endocyte Presents Data at the 2017 CAR-TCR Summit Further Demonstrating the Ability to Manage Cytokine Release Syndrome Related to CAR T-Cell Therapy
- Poster further demonstrates the potential of Endocyte's SMDC CAR-T platform to more safely regulate CAR-T therapy for solid tumors - - Unwanted toxicities may be controlled through the administration of approved agents - WEST LAFAYETTE, Ind. , Sept. 06, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc.
View HTML
Toggle Summary Endocyte Announces Presentation at the European Society for Medical Oncology (ESMO)
WEST LAFAYETTE, Ind. , Sept. 05, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that a poster will be presented at the European Society for Medical
View HTML